Dermatology prior authorization at Independence Blue Cross
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Independence Blue Cross dermatology PA at a glance
Independence Blue Cross reviews dermatology PA submissions against its medical policy library, with rules drawn primarily from AAD (American Academy of Dermatology) + NPF (National Psoriasis Foundation) for psoriasis. Independence Blue Cross-specific context: BCBS licensee covering 5-county SE Pennsylvania (Philadelphia, Bucks, Chester, Delaware, Montgomery). Parent of AmeriHealth (NJ/DE). FutureScripts is the in-house PBM. PA Insurance Department oversees fully-insured complaints.
Documentation packet — what to send
- Diagnosis with ICD-10
- Severity score (PASI, BSA, IGA for psoriasis; EASI, IGA for AD)
- DLQI quality-of-life score
- Prior therapies tried: topicals, phototherapy, oral systemics
- Reason for discontinuation of each prior therapy
Common denial patterns to pre-empt
Patterns observed in dermatology across payers, and where Independence Blue Cross's book of business overlaps:
- Psoriasis: PASI / BSA / IGA severity thresholds not met (typically PASI ≥10 or BSA ≥10%)
- Atopic dermatitis: severity score (EASI ≥21) not documented
- Step therapy through topicals / phototherapy first
- Quality-of-life impact (DLQI ≥10) not documented
- Special sites (face, scalp, hands) not flagged
- Specialty drug PA via FutureScripts (PBM)
Appeal angles when Independence Blue Cross denies
- AAD-NPF guideline citation for psoriasis
- AAD Atopic Dermatitis guideline citation
- DLQI severity argument
- Special-site involvement (face, hands, genitals) supporting expedited biologic
Peer-to-peer prep
- Have photos / clinical findings ready
- Quote the AAD-NPF guideline by year and recommendation grade
- Document failed phototherapy explicitly (NB-UVB, sessions, response)
- For DLQI: state the score AND the specific functional impacts patient reports
Drug-specific PA criteria at Independence Blue Cross
Deep dives on each drug's PA criteria at Independence Blue Cross:
Frequently asked questions
What documentation does Independence Blue Cross need for dermatology prior authorizations?
Independence Blue Cross's PA packet for dermatology typically includes: Diagnosis with ICD-10; Severity score (PASI, BSA, IGA for psoriasis; EASI, IGA for AD); DLQI quality-of-life score; Prior therapies tried: topicals, phototherapy, oral systemics. AAD (American Academy of Dermatology) + NPF (National Psoriasis Foundation) for psoriasis citations strengthen the submission.
What's the turnaround at Independence Blue Cross?
Independence Blue Cross standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which dermatology drugs does Independence Blue Cross most often PA-restrict?
Top targets in dermatology: adalimumab, ustekinumab, secukinumab, guselkumab, risankizumab. Each follows the per-drug step therapy + documentation requirements published in Independence Blue Cross's medical policy library.
How do I prep a peer-to-peer with Independence Blue Cross in dermatology?
Have photos / clinical findings ready Quote the AAD-NPF guideline by year and recommendation grade Have the policy URL and the patient's chart open before the call.
Generate a Dermatology PA packet
Open ApprovalHelp — generate a dermatology PA packet tailored to Independence Blue Cross's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com